Canada House Wellness Group Inc. Accelerates Phenotyping of 62 In-House Genetics

TORONTO, Feb. 14, 2019 (GLOBE NEWSWIRE) — Canada House Wellness Group Inc. (“Canada House” or the “Company”) (CSE:CHV) and Abba Medix Corp. (“Abba”), CHV’s wholly owned Licensed Producer has accelerated their phenotyping program utilizing their state-of-the-art controlled grow facility in Pickering.

Growing since May 8, 2018, Abba Medix Corp. currently has 62 strains in-house. “With our main production area fully online, we have accelerated our phenotyping program and will continue to build our genetics library. The pursuit of superior genetics will never stop at Abba.  Our team knows what patients and recreational consumers expect, and we intend to deliver it,” said Riley McGee, President, Abba Medix Corp.

Utilizing its exclusive partnership with a leading European seed breeder, Abba has carefully curated a library of strains offering a wide range of cannabinoid profiles.  Abba will be working closely with Canada House Clinics (CHC), leveraging their 12,000 plus patients and their proprietary Knalysis Technologies patient management software.

“Canada House’s vertical integration has been designed from day one to bring evidence-based strains to patients. With Canada House Clinic’s medical professionals and diverse patient base, our proprietary software and our state-of-the-art controlled grow facility, we are positioned to become leaders in cannabis genetics. 2019 will be a pivotal year for Canada House Wellness Group Inc. as we claim our spot as leaders in the space,” said Chris Churchill Smith, CEO, Canada House.

Working closely with CHC’s highly qualified staff, Abba seeks to better serve patients and further our understanding of cannabinoid profiles and their respective applications.